TY - JOUR AU - Goadsby, P. J. AU - Holland, P. R. AU - Martins-Oliveira, M. AU - Hoffmann, J. AU - Schankin, C. AU - Akerman, S. PY - 2017 DA - 2017// TI - Pathophysiology of migraine: a disorder of sensory processing JO - Physiol Rev VL - 97 UR - https://doi.org/10.1152/physrev.00034.2015 DO - 10.1152/physrev.00034.2015 ID - Goadsby2017 ER - TY - JOUR AU - Ferrari, M. D. AU - Klever, R. R. AU - Terwindt, G. M. AU - Ayata, C. AU - van den Maagdenberg, A. M. PY - 2015 DA - 2015// TI - Migraine pathophysiology: lessons from mouse models and human genetics JO - Lancet Neurol VL - 14 UR - https://doi.org/10.1016/S1474-4422(14)70220-0 DO - 10.1016/S1474-4422(14)70220-0 ID - Ferrari2015 ER - TY - JOUR AU - Edvinsson, L. PY - 2017 DA - 2017// TI - The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine JO - Headache VL - 57 UR - https://doi.org/10.1111/head.13081 DO - 10.1111/head.13081 ID - Edvinsson2017 ER - TY - JOUR AU - Deen, M. AU - Correnti, E. AU - Kamm, K. AU - Kelderman, T. AU - Papetti, L. AU - Rubio-Beltrán, E. PY - 2017 DA - 2017// TI - Blocking CGRP in migraine patients—a review of pros and cons JO - J Head Pain VL - 18 UR - https://doi.org/10.1186/s10194-017-0807-1 DO - 10.1186/s10194-017-0807-1 ID - Deen2017 ER - TY - JOUR AU - Goadsby, P. J. AU - Reuter, U. AU - Hallström, Y. AU - Broesner, G. AU - Bonner, J. H. AU - Zhang, F. PY - 2017 DA - 2017// TI - A controlled trial of erenumab for episodic migraine JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1705848 DO - 10.1056/NEJMoa1705848 ID - Goadsby2017 ER - TY - JOUR AU - Silberstein, S. D. AU - Dodick, D. W. AU - Bigal, M. E. AU - Yeung, P. P. AU - Goadsby, P. J. AU - Blankenbiller, T. PY - 2017 DA - 2017// TI - Fremanezumab for the preventive treatment of chronic migraine JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1709038 DO - 10.1056/NEJMoa1709038 ID - Silberstein2017 ER - TY - JOUR AU - MaassenVanDenBrink, A. AU - Meijer, J. AU - Villalón, C. M. AU - Ferrari, M. D. PY - 2016 DA - 2016// TI - Wiping out CGRP: potential cardiovascular risks JO - Trends Pharmacol Sci VL - 37 UR - https://doi.org/10.1016/j.tips.2016.06.002 DO - 10.1016/j.tips.2016.06.002 ID - MaassenVanDenBrink2016 ER - TY - JOUR AU - Smillie, S. J. AU - King, R. AU - Kodji, X. AU - Outzen, E. AU - Pozsgai, G. AU - Fernandes, E. PY - 2014 DA - 2014// TI - An ongoing role of α-calcitonin gene-related peptide as part of a protective network against hypertension, vascular hypertrophy, and oxidative stress JO - Hypertension VL - 63 UR - https://doi.org/10.1161/HYPERTENSIONAHA.113.02517 DO - 10.1161/HYPERTENSIONAHA.113.02517 ID - Smillie2014 ER - TY - JOUR AU - Russo, A. F. PY - 2015 DA - 2015// TI - CGRP as a neuropeptide in migraine: lessons from mice JO - Br J Clin Pharmacol VL - 80 UR - https://doi.org/10.1111/bcp.12686 DO - 10.1111/bcp.12686 ID - Russo2015 ER - TY - STD TI - Sabharwal R, Mason BN, Kuburas A, Abboud FM, Russo AF, Chapleau MW. Increased receptor activity-modifying protein 1 in the nervous system is sufficient to protect against autonomic dysregulation and hypertension. J Cereb Blood Flow Metab. 2018; https://doi.org/10.1177/0271678X17751352. ID - ref10 ER - TY - JOUR AU - Lukacs, M. AU - Tajti, J. AU - Fulop, F. AU - Toldi, J. AU - Edvinsson, L. AU - Vecsei, L. PY - 2017 DA - 2017// TI - Migraine, neurogenic inflammation, drug development—pharmacochemical aspects JO - Curr Med Chem VL - 24 UR - https://doi.org/10.2174/0929867324666170712163437 DO - 10.2174/0929867324666170712163437 ID - Lukacs2017 ER -